<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Philadelphia chromosome-negative myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPN), which include <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, and primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, are characterized by clonal proliferative hematopoiesis with increased blood cell count </plain></SENT>
<SENT sid="1" pm="."><plain>Clonal expansion mechanisms in MPN and related disorders such as <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) remain to be elucidated </plain></SENT>
<SENT sid="2" pm="."><plain>Although mutations in the JAK2 gene lead to a proliferative hematopoiesis in majority of MPN and some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the mutation alone does not cause a clonal expansion </plain></SENT>
<SENT sid="3" pm="."><plain>In addition to JAK2 mutations, several genetic abnormalities, including TET2 and polycomb group genes involving epigenetic regulation have been reported in patients with MPN </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, overexpression of HMGA2 due to removal of specific sites in its 3' untranslated region for regulatory let-7 micro <z:chebi fb="40" ids="33697">RNAs</z:chebi> may contribute to the proliferative hematopoiesis with conferring a growth advantage at the level of a hematopoietic stem cell in some cases with MPN </plain></SENT>
</text></document>